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Aim: The purpose of this study was to compare visual outcomes, surgical time, and perioperative 
surgical complications after intracameral use of either phenylephrine/ketorolac (P/K) or 
epinephrine (Epi) during cataract surgery.
Methods: This was a single-center, retrospective case review of patients undergoing cataract 
surgery from August to November 2015. Of the 641 eyes of 389 patients who underwent 
cataract surgery, 260 eyes were administered phenylephrine 1.0%/ketorolac 0.3% and 381 eyes 
received Epi in the irrigation solution intraoperatively. All patients received a topical nonsteroidal 
anti-inflammatory drug regimen (bromfenac 0.07%, nepafenac 0.3%, or ketorolac 0.5%) for 
3 days before surgery and topical tropicamide 1.0%, cyclopentolate 1.0%, and phenylephrine 
2.5% on the day of surgery.
Results: Mean length of surgery (LOS) was 15.4±0.6 minutes. Although a positive correla-
tion was noted between patient age and LOS (p,0.001), P/K was associated with a decrease 
in the LOS, when controlled for age quartiles. A statistically significant lower incidence of 
complications (1.1%) was observed with P/K use than Epi (4.5%; p=0.018). Among surgeons 
who used mydriatic-assist devices more frequently, P/K use was associated with a reduction in 
the use of these devices (p,0.001). When controlling for age quartile, patients of age groups 
69–76 and 76–92 years who received P/K had significantly better uncorrected visual acuity at 
postoperative day 1 than those receiving Epi (p=0.003).
Conclusion: Intracameral use of phenylephrine 1.0%/ketorolac 0.3% during cataract surgery 
may be effective in maintaining mydriasis. It appears to be superior to intracameral Epi at 
reducing intraoperative and postoperative complications, need for pupillary dilating devices, 
and surgical time.
Keywords: cataract surgery, complications, pupillary miosis, phenylephrine, ketorolac
Introduction
Cataract surgery is one of the most frequently performed procedures worldwide. 
Age-related cataracts alone are expected to affect more than 30 million Americans 
by 2020.1,2 Advancements in cataract surgery techniques, technology, and pharma-
ceutical therapies have reduced the risks associated with the procedure and improved 
outcomes. In recent years, cataract surgery has evolved into an outpatient, relatively 
pain-free procedure with rapid recovery of vision. Perhaps as a result, patients now 
have very high expectations of cataract surgery, including a low tolerance for com-
plications and pain.3,4
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A small pupil (,6.0 mm) or intraoperative miosis is 
known to make cataract surgery more technically challenging 
and increase the risk of surgical complications such as 
capsular tears, lens decentration, retained lens fragments, 
postoperative inflammation, or vitreous loss.5–10 One group 
of researchers found a twofold increase in complications with 
each 1.0 mm reduction in pupil size.6
There are a variety of therapeutic treatments aimed at 
improving pupillary dilation and preventing intraopera-
tive miosis, including several topical agents that have been 
approved by the US Food and Drug Administration (FDA) for 
ophthalmic use. Preoperative dilation with topical sympatho-
mimetics, such as phenylephrine, and anticholinergics, such 
as cyclopentolate or tropicamide, have a long track record 
of efficacy. Topical nonsteroidal anti-inflammatory drugs 
(NSAIDs) can also reduce the severity and incidence of intra-
operative miosis by preventing prostaglandin synthesis.11,12 
Topical agents administered preoperatively can, however, 
be washed out of the intracameral space by the irrigation 
solution used during cataract surgery.13 Cardiac sympatho-
mimetics such as epinephrine (Epi) or phenylephrine added 
to the irrigating solution are effective at preventing miosis 
but are not FDA approved for this use and may be subject 
to formulation errors and/or contamination.
Recently, an intracameral combination drug (phenyleph-
rine 1.0%/ketorolac 0.3%, Omidria; Omeros, Seattle, WA, 
USA) intended to be added to the irrigating solution, was 
approved for cataract and intraocular lens replacement 
surgery. Containing both an α
1
-adrenergic receptor ago-
nist and a nonselective cyclooxygenase 1 and 2 inhibitor, 
phenylephrine/ketorolac (P/K) combination has been shown 
to maintain pupillary mydriasis and reduce postoperative 
pain in a Phase III multicenter, randomized study.14
NSAIDs and adrenoceptor agonist agents have a long-
standing history of use in the management of ocular pathology 
and topical ophthalmic preparations. Although intracameral 
ketorolac has not been previously studied during cataract 
surgery, intracameral administration would be expected to 
have some advantages. Since the intracameral combination 
drug is introduced into the operative irrigation solution prior 
to the case, it does not require any modification to current 
surgical techniques or procedures. Additionally, presenting 
the combination therapy intracamerally exposes the target 
tissues to a consistent concentration of drug, maintaining the 
pharmacological effects.14 Other recognized advantages of 
P/K over current techniques include prevention of intraopera-
tive miosis, reduction of pain and discomfort, management 
of postoperative inflammation, reduction in the number of 
pre- and postoperative topical drops, and the availability of 
a bisulfite-free preparation.8,14,15
In the very limited peer-reviewed literature examining 
this combined agent thus far, the drug has not been evalu-
ated in patients with risk factors for intraoperative miosis 
such as intraoperative floppy iris syndrome (IFIS) or 
pseudoexfoliation.8,14 Additionally, while all subjects in 
the FDA trial received standardized topical preoperative 
mydriatics (phenylephrine and tropicamide) and anesthetics 
(lidocaine or tetracaine), they did not receive intracameral 
Epi or a topical NSAID. The purpose of this study was to 
evaluate, in a real-world setting, the incidence of periopera-
tive complications, length of surgery (LOS), and use of pupil 
dilation devices in a broad patient population, including those 
with comorbid conditions that would make surgery more dif-
ficult, such as IFIS, pseudoexfoliation, and otherwise poorly 
dilating pupils. To reflect common clinical practice, the P/K 
treatment group was compared to a control group receiving 
intracameral Epi, and all patients in the study received 
standard preoperative topical NSAIDs.
Methods
A single-center retrospective case review was performed 
for all cataract surgeries taking place at Island Eye Surgical 
Center, Carle Place, NY, over a 3-month period from August 
2015 to November 2015, plus associated first-eye procedures 
as described below. Four surgeons (EDD, GD, JB, and RJL) 
were selected as having performed more than five cataract 
surgeries per week during the review period, including cases 
using intracameral P/K (Omidria) and cases using intra-
cameral Epi without P/K. If the cataract surgery performed 
between the inclusion dates was a second-eye surgery, that 
subject’s first-eye surgery was included in the retrospective 
review as well, as long as the first eye underwent surgery after 
January 1, 2014. Exclusion criteria were age younger than 
21 years, documented sensitivity to NSAIDs, and planned 
combined cataract and posterior segment surgeries. All 
other procedures performed by the selected surgeons during 
the review period were included. The study was conducted 
according to the tenets of the Declaration of Helsinki; addi-
tionally, this research was exempt from Institutional Review 
Board approval under the HHS policy: 45 CFR 46.101(b).
All patients received a topical NSAID regimen (bro-
mfenac 0.07%, nepafanac 0.3%, or ketorolac 0.5%) for 3 days 
before surgery. On the day of surgery, all patients received 
topical tropicamide 1%, cyclopentolate 1%, and phenyleph-
rine 2.5%. Depending upon the insurance coverage, either 
phenylephrine 1%/ketorolac 0.3% or Epi was used in the 
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irrigation solution. P/K was stored between 20°C and 25°C 
and protected from ambient light at all times prior to use. 
Before each P/K case, one 4 mL single-patient-use vial of the 
combination drug was added to a 500 mL bottle of irrigation 
solution in the surgical suite. Once added to the irrigation 
solution, the drug was delivered intracamerally within the 
4-hour recommended time frame. In the remaining patients, 
1 cc of 1:1,000,000 concentration of bisulfite-free Epi was 
added to the irrigation solution.
Each chart was reviewed for surgeon name, date of sur-
gery, age at time of surgery, sex, eye, use of the femtosecond 
laser, use of mydriatic-assist devices (Malyugin rings or iris 
hooks), use of P/K, history or current use of α
1
 antagonists, 
and perioperative complications. In addition, the charts of 
one surgeon (EDD, n=310 eyes) were reviewed for best-
corrected visual acuity (BCVA) and uncorrected visual acuity 
(UCVA) preoperatively and at postoperative day 1 (POD 1) 
and month 1 (POM 1). All visual acuities were converted 
from Snellen to decimal format in order to facilitate calcula-
tion and statistical analysis.
Results were analyzed by age quartile. For statistical 
analyses, Student’s t-tests, correlation tests, z-score, analysis 
of variance (ANOVA), two-way ANOVA, and χ2 tests 
were utilized where appropriate. A p-value of ,0.05 was 
considered significant. Regression models were fit to adjust 
for imbalance in group characteristics, and to assess the 
overall impact of independent variables on the outcomes of 
interest. Statistical analyses were performed using RStudio 
(https://www.r-project.org) and Excel (Microsoft Corporation, 
Redmond, WA, USA).
Results
Surgeons EDD, GD, JB, and RJL performed a total of 
653 cataract surgery procedures during the review period. 
Twelve eyes were excluded based on previously indicated 
exclusion criteria. Of the 641 eyes of 389 patients analyzed, 
413 were of female patients and 228 male; 323 were right 
eyes and 318 were left eyes. Fifty-three eyes had a positive 
history for α
1
 antagonist use. Two hundred seventy-eight eyes 
underwent pretreatment with the femtosecond laser. Of the 
641 eyes, 260 were administered P/K intraoperatively, while 
the remaining 381 had Epi. The average age of a patient 
receiving phenylephrine/ketorolac was 75.4±0.9 years, while 
the average of a patient receiving Epi was 67.4±1.1 years 
(p,0.001). A mydriatic-assist device (Malyugin ring or iris 
hooks) was required to maintain mydriasis in 45 eyes.
Overall, the group receiving P/K were older than the 
group receiving Epi (Student’s t-test, p,0.0001), and more 
patients were female (Student’s t-test, p=0.0016) (Table 1). 
When comparing treatment groups across surgeons, the mean 
age of the groups receiving either P/K or Epi was significantly 
different (χ2, p=0.045 and p,0.0001, respectively), but the 
percent of female patients receiving P/K was similar for 
all surgeons (χ2, p=0.056). For both treatment groups, the 
percent of patients undergoing femtosecond laser was not 
significantly different overall (p=0.0980).
Table 1 Characteristics of eligible patients
Surgeon Treatment N Mean age, 
years (SD)





Overall P/K 260 75.5 (7.2) 71.5 50.4 47.3 8.1
epi 381 67.4 (10.7) 59.6 51.2 40.7 8.4
p-value ,0.0001 0.0016 0.8433 0.0980 0.8843
eDD P/K 141 74.7 (7.1) 68.8 50.4 52.5 6.4
epi 169 63.5 (10.8) 55.6 49.7 54.4 5.9
p-value ,0.0001 0.0168 0.9096 0.7321 0.8658
JB P/K 32 77.6 (6.3) 87.5 53.1 21.9 6.3
epi 59 71.3 (9.5) 74.6 50.8 16.9 10.2
p-value 0.0003 0.1210 0.8382 0.5825 0.5075
gD P/K 28 75.5 (7.6) 82.1 46.4 39.3 7.1
epi 79 69.7 (10.9) 72.2 50.6 36.7 8.9
p-value 0.0027 0.2691 0.7076 0.8136 0.7724
rJl P/K 59 76.8 (7.3) 64.4 50.8 52.5 13.6
epi 74 70.8 (8.2) 43.2 52.7 32.4 12.2

















Abbreviations: epi, epinephrine; P/K, phenylephrine/ketorolac; sD, standard deviation.





The average LOS was 15.4±0.6 minutes, ranging from 
13.0±1.0 to 17.2±1.3 (Figure 1A and B). A positive correla-
tion was noted between age and LOS (p,0.001) (Figure 1C). 
LOS was not exclusively dependent on sex (Student’s t-test, 
p=0.732) or eye (p=0.694), or use of P/K (p=0.676). However, 
when controlling for age quartile, the use of P/K was associ-
ated with a decrease in the LOS in most of the age quartiles 
compared to Epi (oldest quartile, age 78–92: 15.6±1.5 minutes 
vs 16.7±1.2 minutes; age 71–77: 16.0±1.8 vs 16.2±1.5; age 
65–70: 13.7±1.7 vs 17.2±1.7; and youngest quartile, age 
30–64: 10.2±3.7 vs 13.6±1.1; two-way ANOVA, p=0.049) 
(Figure 1D). In patients who received mydriatic-assist devices, 
or patients using α
1
 antagonists, the average LOS was longer 
(19.4±2.6 minutes vs 15.0±0.6 minutes, p,0.001, and 18.5±2.7 
minutes vs 15.1±0.6 minutes, p,0.001, respectively). Interest-
ingly, depending on the surgeon, utilizing the femtosecond 
laser either made surgeries quicker (EDD), slower (RJL), or 
did not affect the time (GD, JB) (Figure 1E).
Older age was associated with the use of mydriatic-
assist devices (76.3±2.4 years vs 70.2±0.8 years, Student’s 
t-test, p,0.001) and α
1
 antagonist use (75.4±0.9 years vs 
67.4±1.0 years, p,0.001). Patients electing to undergo pretreat-
ment with the femtosecond laser were on average younger than 
those who preferred the traditional approach (69.4±1.2 years 
vs 71.6±1.1 years, Student’s t-test, p=0.005).
Complications noted during this study include dislocated 
lens with intraocular lens exchange or repositioning, retained 
lens fragments, lens fragments in the vitreous, wound leak-
age, capsular tear (with or without anterior vitrectomy), 
macular puckering following surgery, and retinal detach-
ment following surgery. In total, 20 adverse events were 
recorded, for a complication rate of 3.1%. The incidence 
of complications was not associated with age (Student’s 
t-test, p=0.757). Complications were independent of surgeon 
(χ2 test, p=0.454), sex (p=0.371), eye (p=0.184), or history or 
current use of α
1
 antagonists (p=0.775). A higher incidence 
of complications was noted when mydriatic-assist devices 
were used (11.1% vs 2.5%, χ2 test, p=0.001), and a lower 
incidence of complications was appreciated when P/K was 
used (4.5% vs 1.1%, χ2 test, p=0.018) (Figure 2A and B). 
Complications occurred most frequently when mydriatic-
assist devices were used in conjunction with intracameral 
Epi; conversely, complications occurred least frequently 
when P/K was administered without a mydriatic-assist device 
(χ2, p=0.001) (Figure 2C). There were no hemodynamically 
adverse events reported with P/K use intraoperatively.
Patients who had a history of, or were currently using, 
α
1
 antagonists were more likely to require mydriatic-assist 
devices (41.5% vs 3.9%, χ2, p,0.001). Patients who under-
went pretreatment with the femtosecond laser were less 
Figure 1 (A) Frequency distribution and average lOs in the study population. (B) lOs by all four surgeons (eDD, gD, JB, and rJl). (C) Correlation between patient age and 
lOs. (D) The average lOs in different age groups in P/K and epi groups. (E) The average lOs by each surgeon in femtosecond laser and manual cataract surgery.
Abbreviations: epi, epinephrine; P/K, phenylephrine/ketorolac; lOs, length of stay.
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likely to require mydriatic-assist devices (3.6% vs 9.6%, 
χ2, p=0.003) (Figure 3A). Mydriatic-assist devices were 
independent of P/K use (χ2, p=0.306). However, in surgeons 
who used mydriatic-assist devices more frequently, the use 
of P/K was associated with a reduction in the use of these 
devices (χ2, p,0.001) (Figure 3B). The use of P/K was also 
associated with a decreased need for mydriatic-assist devices 
in patients using α
1
 antagonists; however, this finding was 
not statistically significant due to the sample size (50% vs 
28.6%, χ2, p=0.121, n=53) (Figure 3C).
The average preoperative BCVA was 0.50 (±0.03), while 
POD 1 and POM 1 UCVA were 0.40 (±0.03) and 0.78 (±0.03) 
respectively. There was no statistically significant difference 
in POD 1 UCVA or POM 1 BCVA between patients receiving 
P/K and those receiving Epi overall (Figure 4A). However, 
when controlling for age quartile, patients receiving P/K 
had significantly better POD 1 UCVA than those receiving 
Epi among the older two quartiles (age 69–76, 0.44±0.08 vs 
0.38±0.10); age 76–92 (0.34±0.06 vs 0.23±0.08) (two-way 
ANOVA, p=0.003) (Figure 4B).
To assess the overall impact of independent variables on 
the outcomes of interest, logistic regression models were fit to 
adjust for the effect of surgeon, age quartile, sex, use of P/K, 
use of femtosecond laser, and α-antagonist use on the rate 
of complications and utilization of mydriatic-assist devices. 
In the overall sample, older age was associated with an 
increased rate of complications (p=0.01203), while use of P/K 
was associated with a significantly smaller rate of complica-
tions (p=0.0031) compared to Epi. Use of mydriatic-assist 
devices varied somewhat by surgeon, and was significantly 
Figure 2 (A) Complication rate in eyes with or without mydriatic-assist device use. (B) Complication rate in P/K and epi groups. (C) Complication rate with or without 
mydriatic-assist device use in P/K and epi groups.
Abbreviations: epi, epinephrine; P/K, phenylephrine/ketorolac.





lower in patients who underwent femtosecond-assisted laser 
procedures.
A linear regression model was fit to evaluate the effect 
of surgeon, age quartile, sex, use of femtosecond laser 
during surgery, and α-antagonist use on the length of sur-
gical time. Overall, three surgeons (GD, JB, and RJL) all 
had significantly longer surgical times compared to EDD 
(p,0.05). Older age and use of α-antagonist medication 
were also associated with longer surgical times (p=0.0285 
and p=0.0033, respectively).
Discussion
A previous study demonstrated the superiority of P/K vs 
placebo in maintaining mydriasis and reducing postoperative 
pain.14 This single-center, retrospective case study assessed 
the perioperative complications, surgical time, and visual 
outcomes of intracameral P/K vs Epi in a real-world setting. 
All patients received 3 days of preoperative topical NSAID, 
which was not given in the FDA trial. In addition, the control 
group in our study was administered intracameral Epi, which 
was not used in the FDA trial. Given the unique opportunity 
to study this drug in a typical practice setting, it was possible 
to analyze outcomes in a real-world treatment setting. Due to 
inclusion criteria in this study, patients receiving P/K were 
on average 8 years older than the control group receiving 
Epi-infused surgical irrigation fluid. Given the propensity for 
older individuals to have a positive history for α
1
-antagonist 
use, and the increased likelihood for mydriatric-assist device 
placement in older patients, it was surprising to find that 
perioperative complications remained fourfold less when the 
surgical protocol included P/K. Upon further investigation, 
there was a 17-fold increase in complications when mydriatic-
assist devices were used in conjunction with intracameral Epi 
compared to cases with P/K and no mydriatic-assist devices; 
however, it should be noted that complications were halved 
when P/K was used in conjunction with a mydriatric-assist-
device. It is conceivable that P/K increased overall visibility, 
thereby decreasing complication risk.7,16
One can assume that if a Malyugin ring or iris hooks 
were used intraoperatively, the surgeon judged the pupil to 
be miotic or considered there to be significant risk of miosis 
that warranted a pupillary expansion device.7 In the current 
study, we found a fourfold increase in complications associ-
ated with the use of mydriatic-assist devices. This increase 
α α
Figure 3 (A) Mydriatic-assist device rate in eyes that underwent femtosecond laser-assisted cataract surgery and manual surgery. (B) Mydriatic-assist device rate by each 
surgeon in P/K and epi groups. (C) Mydriatic-assist device rate in patients with or without history of α1 antagonist use in P/K and epi groups.
Abbreviations: epi, epinephrine; P/K, phenylephrine/ketorolac.








Figure 4 (A) UCVa at POD 1 and BCVa at POM 1 in P/K and epi groups. (B) POD 1 UCVa in different age groups in P/K and epi groups.
Abbreviations: BCVa, best-corrected visual acuity; epi, epinephrine; P/K, phenylephrine/ketorolac; POD 1, postoperative day 1; POM 1, postoperative month 1; UCVa, 
uncorrected visual acuity.
in complications is thought secondary to the complexity 
of these types of cases, which are not uncommon in this 
referral group. Supporting this theory, we presented here 
that the use of P/K in α
1
-antagonist patients and the appli-
cation of femtosecond laser in cataract surgery decreased 
the dependence on mydriatic-assist devices (-twofold and 
threefold, respectively). Additionally, in surgeons who used 
mydriatric-assist devices more frequently than 10% of the 
time, the application of P/K was found to decrease the need 
for mechanical dilatation.
Overall, there was no detectable difference in visual acu-
ity between patients receiving P/K vs Epi-infused irrigation 
solution at POD 1 or POM 1. However, when controlling for 
age quartile, there was a significant improvement in POD 1 
UCVA in the P/K eyes compared to the Epi eyes among the 
older age groups. The immediate improvement in POD 1 
visual acuity may be attributed to the anti-inflammatory 
properties of ketorolac. Furthermore, the LOS was shorter 
in three of the four age quartiles when using P/K, indepen-
dent of femtosecond laser application, which may have also 
contributed to the better postoperative results.
This study has several limitations worth noting. First, it 
was a single-center study with four surgeons, which may limit 
the generalizability of this study to other centers. With four 
surgeons, the total treatment effect may be confounded by dif-
fering technique or differing patient populations. We showed 
that the patient populations differed among surgeons by age, 
sex, and use of femtosecond laser. It is not clear whether 
these variables influenced the results in any tangible way. 
Additionally, it was a retrospective case review looking at a 
cohort of patients over a 4-month interval. While retrospec-
tive analyses lack the strength of a prospective, randomized 
trial, in this real-world setting a retrospective review may in 
fact decrease some elements of bias, particularly regarding 
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surgeon performance. Therefore, the retrospective nature of 
this study best reflects the outcomes that occur in a natural 
practice setting. The window of analyzing complications 
ranged from 2 months to 1 year depending on the original 
date of surgery, which could lead to a lower number of 
complications detected among patients with the shortest 
follow-up. Patients were selected to receive P/K based on 
insurance status, which likely played a role in the older age 
in that group, but also may have introduced unintentional 
bias between treatment groups beyond the demographic 
information captured in Table 1. It is reasonable to suggest, 
however, that the older patients in the P/K group may have 
had a greater risk for complications, which would in fact 
attenuate the treatment effect. It should be noted that in this 
study the femtosecond laser was not utilized in patients with 
pupils ,5 mm in size. Lastly, because complications were 
relatively infrequent, significant results were not always 
obtainable from the small sample sizes.
Conclusion
Cataract surgery is a well-established surgical procedure that 
provides expeditious functional visual improvement. Over 
time, innovation and improvement in existing procedural 
techniques along with pharmaceutical advancements have 
allowed cataract surgeons to reduce risk, enhance visual 
outcomes, and increase patient satisfaction. The addition of 
P/K to the surgeon’s regimen has been shown previously 
to maintain mydriasis and decrease postoperative pain.14 In 
this study, we also showed a decrease in intraoperative and 
postoperative complications, a reduction in the need for pupil-
lary dilating devices, decreased age-adjusted surgical time, 
and an improvement in POD 1 UCVA in patients $69 years 
of age.
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